Stockreport

Neurogene Reports Full Year 2025 Financial Results and Highlights Recent Updates [Yahoo! Finance]

Neurogene Inc.  (NGNE) 
PDF NGN-401 has been generally well-tolerated in Phase 1/2 trial and Embolden, with no cases of HLH at the 1E15 vg dose; additional interim Phase 1/2 data expected mid-2026 [Read more]